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Abstract 
A prospective, randomized controlled trial was conducted to determine the effect 
of phenobarbitone on neonatal jaundice and to derive pharmacokinetic parameters 
for South African Black African neonates. The study group comprised 22 term babies 
given phenobarbitone 12mg/kg intramuscularly as a single dose plus phototherapy. 
The 22 controls were given phototherapy only. There was no significant difference 
in the mean serum bilirubin levels for the 2 groups at 20 hours, 48 and 96 hours. 
It is concluded that phenobarbitone at this dose does not significantly decrease 
total serum bilirubin levels nor the duration of hospital stay in term babies with 
neonatal jaundice. NONMEM analysis of serum phenobarbitone data in this study 
resulted in clearance (Cl) of 0.008 I/hr and a volume of distribution (Vd) of 0.84 
I/kg with an intra-individual variability of 8.8%. These pharmacokinetic values, which 
are the first to be reported for Black South African neonates, are consi�tent with 
those reported in the literature. 
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ALL SEEMS INFECTED THAT TH' INFECTED SPY, 
AS ALL LOOKS YELLOW TO THE JAUNDICED EYE. 
1 
- Alexander Pope
An Essay on Criticism, 1711. 
Two out of three full-term newborns are clinically jaundiced in the first few days after birth. 
Each year at least half of the newborns in the nursery have at the minimum one bilirubin 
determination performed (Newman and Maisels, 1990). 
Although clinicians devote most of their efforts to the salvage of tiny infants, a good deal 
of recent clinical research has explored the problem of jaundice in the healthy full-term infant. 
The physician has to decide when to obtain a serum bilirubin measurement in a jaundiced 
infant; when to perform further investigations; when to initiate some form of intervention 
and how to reassure the family that "in spite of our meddling" the baby really is normal 
and will not suffer any long term consequences. Here, the mother can neither anticipate 
the need for numerous bilirubin determinations, nor can she be asked to leave her infant 
in the hospital, blindfolded and receiving phototherapy and other forms of intervention. 
2 
Jaundice, phototherapy, eye shields and exchange transfusion cause a great deal of maternal 
anxiety. 
Hyperbilirubinaemia is of concern in neonates because of the risk of bilirubin toxicity to 
the central nervous system, that is, bilirubin encephalopathy and kernicterus. Bilirubin 
encephalopathy can be prevented but cannot be reversed once it has occurred. Thus the goal 
of treatment of neonatal jaundice is the prevention of kemicterus and other documented or 
suspected sequelae of bilirubin encephalopathy. 
For practical purposes, a simplified version of the pathogenesis of bilirubin encephalopathy 
has to be accepted, according to which plasma bilirubin levels are of paramount importance, 
inspite of, other factors contributing to bilirubin toxicity. Thus, efficacy of treatment is 
judged by the ability to reduce the intensity and duration of hyperbilirubinaemia and, as 
a consequence, the frequency of exchange transfusion. 
Drug treatment of neonatal jaundice presents both theoretical opportunities and difficulties. 
The opportunities arise from the fact that for most newborns, jaundice is the expression of 
a transient delay in the transition from intrauterine to extrauterine patterns of bilirubin 
elimination. The transient nature of the difficulty allows for treatment to be of short duration 
and effective treatment need not be anything more than the acceleration of a naturally occurring 
maturational process. The difficulty arises from the fact that, as with all other preventive 
measures, many subjects have to be treated in order to prevent the condition in a few. 
3 
However, the arguments in favour of the pharmacological management of neonatal _jaundice 
is reduced to the evidence that this therapy decreases the complexity and costs of treatment 
of hyperbilirubinaemia without increasing immediate morbidity or long-term sequelae. Fu1ther­
more, maternal bonding and breast feeding is enhanced because there is no separation in 
this crucial phase. Another potential benefit of phenobarbitone treatment is a reduction in 
the duration of phototherapy and the need for hospitalization. 
There is great difficulty in assessing the effectiveness of pharmacological management of 
neonatal jaundice in the post phototherapy era. As with exchange transfusion, phototherapy 
has to be included in the protocol of studies on drug treatment in neonatal jaundice. 
This results in blunting of the differences in bilirubin values between the control and 
experimental groups. The additional difference between the groups becomes the parameter 
by which the efficacy of the drug treatment may be judged. There is a moral and ethical 
obligation not to deprive the experimental group of the proven benefits of photo therapy and 
yet demonstrate the effect of the new treatment. 
Exchange transfusion is incorporated into all protocols, because it is the gold standard in 
the management of severe hyperbilirubinaemia and the prevention of bilirubin toxicity, especially 
jaundice within the first 24 hours and in neonates with blood group incompatibilities and 
haemolysis. 
4 
Purpose Of Study 
1. To assess the role of parenteral phenobarbitone m the management of neonatal
hyperbilirubinaemia.
2. To make recommendations on the future use of phenobarbitone in neonatal jaundice.
3. To derive pharmacokinetic data for parenteral phenobarbitone in neonates.
Importance Of Study 
The investigation of phenobarbitone in neonatal jaundice is primarily directed towards: 
1. A Third World population group with a high risk of severe neonatal jaundice and scarcity
of resources for its management, especially exchange transfusion or immunoglobulins.
2. The reduction of the risks associated with exchange transfusion especially in this AIDS
awareness era. The other risks associated with exchange transfusion are:
- the transmission of potentially serious infections
- mild graft versus host reactions
- the difficulty of the procedure and
- the associated morbidity and mortality ( < 1 % ).
3. The determination of pharmacokinetic parameters of
phenobarbitone which are important in dosage design.
5 
CHAPTER2 
2.1 Review Of Literature 
Interest in using phenobarbitone to decrease neonatal hyperbilirubinaemia was generated 
following the retrospective study of Trolle (1968), who reported a diminished incidence 
of neonatal jaundice among the off springs of epileptic and pre-eclamptic women treated with 
phenobarbitone during their pregnancies. This original report led to the assessment of 
the administration of phenobarbitone post-natally for hyperbilirubinaemia. The post-natal 
use offered the advantage of focusing the treatment to easily identifiable high risk groups. 
A retrospective analysis of the problem of neonatal jaundice (NNJ) at King Edward VIII 
Hospital for the one year period April 1992 to March 1993 showed that there were 2799 
cases of neonatal jaundice of which 195 (14.35%) required exchange transfusions 
(Appendix A). 
In all studies for the treatment of neonatal hyperbilirubinaemia using phenobarbitone 
(Table I), the treatment group had lower mean bilirubin values than the control group starting 
from day 3, with the maximum difference being reached on day 5 or later (Valaes and Harvey­
Wilkes, 1990). The occurrence of jaundice and the need to perform an exchange transfusion 
was also decreased, particularly in the low-birth weight infants. In some of the studies, 
the small sample size prevented this effect from reaching statistical significance. However, 
the consistency of the trend, favours the conclusion that phenobarbitone at a dose of 5-
6 
lOmg/kg/per day given orally or intramuscularly for the fr st 4 to 5 days of life will decrease 
the incidence of jaundice. 
Other retrospective trials (some of which not mentioned in Table I) also give credence to 
the use of phenobarbitone. 
In 1969, Yeung and Field conducted a randomised controlled study on 210 Chinese jaundiced 
neonates. Of these 93 were given phenobarbitone and 117 were used as controls. In the 
phenobarbitone group, only 4 patients (4.3%) required exchange transfusion whereas 53 
patients ( 45. 3 % ) required an exchange transfusion in the control group. This difference 
in the results was statistically significant (p= <0.001), especially in babies with ABO 
incompatibility, glucose-6-phosphate deficiency and cephalhaematoma. However, in a similar 
study in full term infants Cunningham, ctal. (1969) showed no significant decrease in serum 
bilirubin level. 
In 1970, Levin, et al. conducted a controlled study of 24 patients with neonatal jaundice. 
All the infants were given oral phenobarbitone at a dose of 5mg 8 hourly for patients greater 
than 2.5kg and 5mg 12 hourly for patients less than 2.5kg. They noted a significant decrease 
in bilirubin levels (p < 0. 05) in both groups. 
In a randomized study of 38 patients by Valdes, et al. in 1970, 23 patients were given 
phenobarbitone 5mg/kg/day orally for 3 days and 15 patients were used as controls. A 
significant decrease in serum bilirubin occurred on day 3 in the treatment group. 
7 
In 1973, Wong and Wood studied the effect of phenobarbitone in 3 groups of jaundiced 
neonates. Group 1 was given phototherapy only, group 2 was given phenobarbitone only 
and group 3 was given a combination of phototherapy and phenobarbitone. 
The dose of phenobarbitone used in groups 2 and 3 was 8mg/kg/day administered 
intramuscularly as 3 injections daily for a total of 10 doses. Groups 1 and 3 yielded similar 
results, with a significant fall in bilirubin occurring from 24 hours onwards. Hence combined 
phototherapy and phenobarbitone treatment showed no difference from phototherapy alone. 
The phenobarbitone group (group 2) had significantly higher levels of bilirubin up to 60 












































































































































































































































































































































































































































































































































































































































































































































































2.2 Neonatal Hyperbilirubinaemia 
2.2. 1 INTRODUCTION 
We have heen writing, talking and worrying about neonatal jaundice for more than a century­
since Orth, in 1875, first observed bilirubin pigment in the brain of infants dying from severe 
jaundice. Yet, in spite of great strides made in our understanding of bilirubin biochemistry 
and the development of an armamentarium for the evaluation and treatment of hyperbilirub­
inaemia, some of the most hasic questions remain unanswered, namely 
• What is the mechanism of bilirubin encephalopathy?
• How are the risks of hyperbilirubinaemia evaluated?
• Does bilirubin damage the brain of healthy full term infants?
These are important issues as two out of three full-term newborns are clinically jaundiced 
in the first few days after birth. Thus, we can look forward to many more decades of research 
before we have all, or even most, of the answers. 
2.2.2 STRUCTURE OF BILIRUBIN 
The structure of bilirubin as shown in Figure 1 is essentially 4 pyrrole rings joined by 3 
single carbon bridges. For the middle 2 pyrrole rings, the bridge is a single bond and for 
the outer two rings, the bridges are double bonds. Each double bond can exist in two different 
arrangements or configurations. Such configurations are now designated as Z and E, the 
equivalent of cis and trans respectively. In bilirubin IX alpha, the configuration of these 
two double bonds are set by configurations in the parent heme molecule where they are both 
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BIOSYNTHESIS OF BILIRUBIN -
HEME DEGRADATION PATHWAY 
Modified from Clinics of Perinatology, June 1990 
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2.2.3 BIOSYNTHESIS (FIGURE 2) 
Most of the bilirubin formed in the tissue by the breakdown of haemoglobin is bound to 
albumin in the circulation. Heme is degraded to biliverdin through the concerted action 
of the microsomal enzymes heme oxygenase and nicotinamide - adenine dinucleotide phosphate 
(NADPH) cytochrome cP450 reductase and via the cytosolic enzyme biliverdin reductase 
to bilirubin (Yoshinaga, et al. 1982). 
The current hypothesis proposes that the enzyme complex promotes the auto-catalysis of 
heme. This hypothesis is supported by recent studies of the heme oxygenase gene that identified 
inducer element binding sites responsive to metal administration, heat shock and nutrient 
availability. Several metalloporphyrins, such as tin and zinc porphyrin complexes, inhibit 
heme oxygenase activity and thus have therapeutic potential for the treatment of neonatal 
jaundice (Drommond, et al. 1981). 
2.2.4 METABOLISM AND EXCRETION 
Figure 3 describe the metabolism and excretion of bilirubin. The free bilirubin enters the 
liver cell where it is bound to cytoplasmic proteins. It is conjugated to glucuronic acid in 
a reaction catalysed by the enzyme glucuronyl transferase. This enzyme is located primarily 
in the smooth endoplasmic reticulum. Each bilirubin molecule binds two glucuronic acid 
molecules. The source of glucuronic acid is uridine diphosphoglucuronic acid (UDPGA). 
The bilirubin glucuronide, which is more water soluble than free bilirubin, is then transported 
against a concentration gradient by a presumably active process into the bile canaliculi. 
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Modified from Guyton, A.C.: Textbook of Medical Phsyiology, 6th ed. 
Philadelphia. W.B. Saunders Company, 1981. 
15 
The intestinal mucosa is relatively impermeable to conjugated bilirubin but is permeable 
to unconjugated (indirect) bilirubin and to urobilinogens, a series of colourless derivatives 
of bilirubin formed by the action of bacteria in the intestine. Consequently some of the 
bile pigments and urobilinogens are reabsorbed into the portal circulation. Some of the 
reabsorbed substances are again excreted by the liver (enterohepatic circulation), but small 
amounts of urobilinogen enter the general circulation and are excreted in the urine. In 
conclusion plasma bilirubin normally includes free bilirubin plus conjugated (direct) bilirubin. 
The life-cycle of bilirubin is summarised in Figure 4. 
The free bilirubin is measured as the indirect-reacting bilirubin and the conjugated bilirubin 
is measured as the direct reacting bilirubin (Guyton, Textbook of Medical Physiology, 6th 
edition, 1981). 
16 
2.2.5 ETIOLOGY OF NEONATAL JAUNDICE (TABLE II) 
The etiology of neonatal jaundice as described in Nelson, Textbook of Paediatrics, 13th edition, 
(1987) is summarised below. The metabolism of bilirubin in the newborns is in transition 
from the foetal stage, during which the placenta is the principal route of elimination of the 
lipid soluble bilirubin, to the adult stage, during which the water soluble conjugated form 
is excreted from the hepatic cell, into the biliary system and then into the gastrointestinal 
tract. 
Jaundice may be due to any factor that: 
1. Increases the load of bilirubin to be metabolised by the liver, e.g.
a. haemolytic anaemias
b. shortened red cell life owing to immaturity or to transfused cells
c. increased enterohepatic circulation
d. infection





3. May compete for or block the enzyme, e.g.
a. drugs
b. other substances requiring glucuronic acid conjugation for excretion
���i�sia1■11
DIAGNOSTIC FEATURES OF THE VARIOUS TYPES OF NEONATAL JAUNDICE 
DIAGNOSIS NATURE OF VAN PEAK BILIRUBIN CONC. PEAK BILIRUBIN CONC. BILIRUBIN RATE OF REMARKS 
BERGH REACTION ACCUMULATION 
APPEARS DISAPPEARS mg/dL AGEIN DAYS 
1. 'Physiologic jaundice': 1. Usually relates to degree of maturity
Full-term Indirect 2-3 days 4-5 days 10-12 2-3 <5 
Premature Indirect 3-4 days 7-9 days 15 6-8 <5 
2. Hyperbilirubinemia due 2. Metabolic factors: Hypoxia, respiratory
to metabolic factors, etc: distress, lack of carbohydrate.
Full-term Indirect 2-3 days Variable >12 1st week <5 Hormonal Influences: cretinism,
Premature Indirect 3-4 days Variable >15 1st week <5 hormones.
Genetic factors: Crigler-Najjar syndrome,
transient familial hyperbilirubinemia.
Drugs: Vitamin K. Novobiocin
3. Hemolytic states and Indirect May appear in 1st 24 hrs Variable Unlimited Variable Usually >5 3. Erythroblastosis: Rh, ABO.
hematoma Congenital hemolytic states: spherocytic,
nonspherocytic, Infantile pyknocytosis.
Drugs: Vitamin K. Enclosed hemorrage -
hematoma.
4. Mixed hemolytic and Indirect and direct May appear in 1st 24 hrs Variable Unlimited Variable Usually >5 4. Infection: bacterial sepsis, pyelonephritis,
hepatotoxic factors hepatis, toxoplasmosis, cytomegalic
inclusion disease, rubella
Drugs: vitamin K.
5. Hepatocellular damage lndrect and direct Us�ally 2-3 days Variable Unlimited Variable Variable can be >5 5. Biliary atresia; galactosemia; hepatitis and
infection as in ( 4).




4. Leads to an absence of or decreased amount of the enzyme or to the reduction of
bilirubin uptake by the liver cells, e.g.
a. genetic defect
b. prematurity
The risks of toxic effects from elevated levels of bilirubin in the serum is increased by factors 
that 
1. Decrease the retention of bilirubin in the circulation e.g. hypoproteinaemia, displace­
ment of bilirubin from its binding sites on albumin by competitive binding of drugs
such as sulfisoxazole, acidosis, hyperosmolality, increased free fatty acid concentration
secondary to hypoglycaemia, starvation or hypothermia;
2. Increase the permeability of the blood-brain barrier or nerve cell membranes to
bilirubin or the susceptibility of brain cells to its toxicity such as asphyxia, prematurity
and infection.
The differential diagnosis of neonatal jaundice is summarised in Table III. 
DIFFERENTIAL DIAGNOSIS OF NEONATAL JAUNDICE 
A. Present at birth or <24 hours
1. Erythroblastosis foetalis
2. Concealed haemorrhage or extensive ecchymosis/ haematoma
3. Sepsis
4 . Cytomegalic inclusion disease, rubella, congenital toxoplasmosis
5. Intrauterine transfusions (high portion of direct reaction bilirubin)
8. Present Day 2 - 3
1. Physiologic (commonest)
2. Hyperbilirubinaemia of the newborn (more severe form)
3. Familial nonhaemolytic icterus viz. Criggler-Najjar syndrome
C. Present Day 4 - 7
1. Septicaemia
2. Other infections eg. syphilis, toxoplasmosis, CMV inclusion disease
D. Present after 1st week
1. Breast milk jaundice
2. Acute bacterial infections - Septicaemia, UT.I.
3. Congenital Biliary Atresia
4. Hepatitis
5. Rubella, Chronic Herpetic Hepatitis
6. Galactosaemia
7. i) Congenital Haemolytic anaemia (Spherocytosis) 
ii) Crises of other haemolytic anaemias eg. pyruvate kinase and other glycolytic
enzyme deficiencies, thalassaemia, sickle cell disease, hereditary
nonspherocytic anaemia.
iii) Haemolytic anaemia due to drugs eg. in congenital deficiencies of
glucose-6-phosphate dehydrogenase, glutathione synthetase, reductase or
peroxidase.
E. Persistent jaundice During 1st Month
1. lnspissated bile syndrome (which may follow Haemolytic disease of the newborn)
2. Hyperalimentation associated cholestasis
3. Hepatitis
4. CMV Inclusion disease, Toxoplasmosis, Syphilis
5. Familial non haemolytic icterus
6. Congenital Biliary Atresia
7. Galactosaemia
8. Physiological (very rare - especially in hypothyroidism and pyloric stenosis)
19 
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2.2.6 CLINICAL CONSEQUENCES OF MODERATE HYPERBILIRUBINAEMIA 
Newman and Maisels, (1992) in their analysis of various studies, demonstrated that no evidence 
exists to support the view that bilirubin levels of 20mg/dl (340umols/l) are hazardous to 
healthy term infants nor does any evidence suggest that phototherapy has affected cognitive 
or neurologic outcome in any way. 
1. Term Infants
While minor delays in motor development have been demonstrated during the first year, 
this delay was not apparent with long term follow up. Associated conditions such as sepsis, 
anoxia and acidosis may increase the likelihood of neurotoxicity of bilirubin in these infants 
(Kim, et al. 1980). 
2. Pre-term Infants
In this sub group, the neurotoxic consequences are unclear. No acute clinical syndrome 
is recognisable during the first weeks. The commonest consequence is hearing loss (Perlman, 
et al. 1983). 
2.2.7 CLINICAL FEATURES OF BILIRUBIN ENCEPHALOPATHY 
The features of bilirubin encephalopathy vary depending on the age of the infant and the 
degree of hyperbilirubinaemia. 
1. Neonatal Period
In term infants, the clinical features are well documented by Van Praagh (1961) in a study 
21 
of 31 kernicteric infants with haemolytic disease. He described the progression through 
three distinct clinical phases in 18 children who survived the neonatal period. 
First Phase 
Stupor, hypotonia and poor sucking were present in the first few days. In Van Praagh's 
series, 3 infants died during this 1st phase. Although these signs are non-specific, their 
presence is associated with hyperbilirubinaemia encephalopathy. Infants who survive and 
progress to the 2nd phase have a worse prognosis. 
Second Phase 
Hypertonia and fever develop after the first several days. Hypertonia involves extensor muscle 
groups, with most infants exhibiting retrocollis (backward arching of the neck) and opisthotonos 
(backward arching of the trunk). Fever which occurred in 80% of the infants studied by 
Van Praagh (1961) did not relate to any recognised cause and may have been related to the 
diencephalic involvement of kernicterus. 
Third Phase 
This phase is characterised by diminution or disappearance of hypertonia which usually occurs 
after the first week. Although the apparent normalisation of tone is occasionally interpreted 
as evidence against kernicterus, in fact all infants who develop hypertonia of the second 
phase ultimately develop chronic postkernicteric bilirubin encephalopathy (Johnston, 1967). 
22 
2. Post-Neonatal Period
The period following the acute phase is referred to as chronic postkemicteric bilirubin 
encephalopathy with the following consequences: 
Extrapyramidal Disturbances 
Choreoathetosis in particular, may develop as early as 18 months but occasionally is delayed 
until as late as 8 or 9 years. In several affected children, choreoathetosis may prevent useful 
limb function and these unfortunate children may also have severe dysarthria, facial grimacing, 
drooling, difficulty in chewing and swallowing (Byers, et al. 1955). 
Auditory Abnormalities 
Hearing loss may be the only clinical manifestation due primarily to injury to the brainstem 
cochlear nuclei. This is the commonest neurological abnormality in children with chronic 
bilirubin encephalopathy (Johnston, 1967). 
Ocular Abnormalities 
These are characterised by: 
1. Limitation of upward gaze (common).
2. Paralytic gaze palsies.
Intellectual Deficits 
Only the minority of affected neonates have major deficits. This relative sparing of intellect 
in these term infants is consistent with the pathologic observation of relative sparing of the 
cerebral cortex (Byers, et al. 1955). 
23 
2.2.8 THE PASSAGE OF BILIRUBIN INTO THE BRAIN 
Biliruhin can enter the brain via 3 different mechanisms (Figure 5). Firstly, a steady passage 
of unbound bilirubin crosses the blood brain harrier even during physiologic hyper­
bilirubinaemia. This probably colours the brain as well as the CSF yellow. General and 
regional increases in brain blood flow will increase passage of bilirubin across the blood 
brain barrier, owing to increased bilirubin delivery. 
The pathologic significance of this normal brain bilirubin deposition is uncertain. Under 
normal circumstances, this low level of bilirubin in the brain is probably not harmful. However, 
significant behaviourial and neurophysiologic effects of the physiological "brain icterus" 
has been demonstrated in jaundiced neonates. The response to external stimuli, visual 
orientation, attention, alertness and motor pe1formance have been found to be lower in jaundiced 
infants (Ebbesen and Brodersen, 1982). 
Although these changes have usually been found to be reversible, it is not known if this 
also holds true for prolonged hyperbilirubinaemia. Thus it has been suggested that not only 
the peak serum bilirubin concentration but also the duration of hyperbilirubinaemia in the 
infant correlates with neurodevelopmental outcome (Rye, 1981). 
Secondly, increased levels of unbound bilirubin in the blood can be seen in different pathologic 
conditions. These conditions will therefore dramatically increase the entry of bilirubin into 
the brain, similarly increasing binding to the nerve cells. The high concentrations ofunbound 
bilirubin will finally saturate the membranes and cause precipitation ofbilirubin acid (Wennberg, 
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This condition represents the classical picture of kemicterus, seen mainly in rhesus 
isoimmunisation in which the serum bilirubin concentrations exceeds the binding capacity 
of the albumin molecule. 
Such increases in free bilirubin concentrations are also seen in the following situations: 
1. The sick infant whose albumin binds less bilirubin.
2. The premature infant due to low serum albumin.
3. Bilirubin displacement by drugs and free fatty acids (FFA).
Finally, bilirubin can enter the brain through a disrupted blood-brain barrier. In the newborn, 
this is probably most often caused by hypoxaemia, hypercarbia and hyperosmolar conditions, 
but it is also possible that hyperthermia and septicaemia have similar effects. 
The last few decades of bilirubin research seem to have clarified the basic mechanisms by 
which bilirubin enters the brain. Clinical studies have so far failed to show any value of 
the presently known risk factors in predicting bilirubin toxicity in the newborn infant. This 
indicates that bilirubin entry into the brain does not necessarily equal bilirubin toxicity (Kim, 
et al. 1980). Future research must therefore concentrate on further clarifying the molecular 
basis for the interaction between the nerve cell membrane and bilirubin as well as bilirubin 
effects on nerve cell metabolism. 
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2.2.9 DOES HYPERBILIRUBINAEMIA DAMAGE THE BRAIN OF HEAL THY, 
FULL-TERM INFANTS? 
In the 1950's, exchange transfusion to keep the total serum bilirubin (TSB) level below 20mg/dL 
(340 umol/1) was shown to be an effective way of preventing kernicterus in babies with 
erythroblastosis. Subsequently, several investigators showed that babies without Rhesus 
disease were less likely to develop kernicterus and could be managed more conservatively 
(Mollison, et al. 1952). 
Thereafter, several post-mortem observations ofbilirubin staining of the brain in premature 
infants with low bilirubin levels raised new concerns about possible "brain damage" in surviving 
infants who had low levels of bilirubin in the newborn period. 
This information was erroneously extrapolated to healthy full-term infants and undoubtedly 
spurred on by medicolegal pressures, the exchange-transfusion threshold for these infants 
crept downwards. With the introduction of phototherapy, serum bilirubin was lowered 
painlessly, and paediatricians could not be blamed for assuming that it thus reduced the risk 
of bilirubin induced brain damage. 
However, Newman and Maise ls (J 992) after careful analysis of numerous studies, concluded 
that no evidence exists to support the view that bilirubin levels of 20mg/dl is hazardous to 
healthy term infants nor does any evidence suggest that phototherapy has affected cognitive 
or neurologic outcome in any way. 
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The implications of confounding or effect modification by prematurity and haemolysis have 
in the past either not been recognised or have received insufficient attention. Premature babies 
and infants with haemolytic disease have to be considered separately. If they are not, the 
relationship between bilirubin and adverse outcome in well babies is likely to be overestimated. 
Thus, the aggressive treatment of jaundice in term babies without haemolysis is now being 
questioned. Newman and Maisels (1992) have shown that good evidence exists that such 
babies are not at risk of mental or physical impairment until serum bilirubin levels rise well 
above 20mg/dl. 
Hence, before we treat the thousands of babies in our nurseries who daily manifest this benign 
form of neonatal jaundice, we should be sure that the potential benefits of our interventions 
outweigh the risks. Current evidence suggests that this is not the case. 
2.3 Pharmacologic Treatment Of Neonatal Jaundice 
2.3.1 MATERNAL PHENOBARBITONE TREATMENT FOR THE PREVENTION 
OF NEONATAL JAUNDICE 
2.3.1.1 Antenatal Phenobarbitone 
The practical impact of antenatal phenobarbitone prophylaxis of neonatal jaundice was studied 
in Greek neonates, a population characterised by a high incidence of marked jaundice and 
kernicterus due to a high incidence of glucose-6-phosphate dehydrogenase deficiency (G-6-PD) 
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(Val.aes, et al. 1969). The large sample size (total 3075) allowed confident conclusions 
to be drawn regarding the effectiveness of the treatment in reducing the occurrence of dangerous 
hyperbilirubinaemia from all causes in term infants in the pre-phototherapy era (Valaes, 
et al. 1980). 
In the infants of mothers who received at least ten nightly doses of 100mg phenobarbitone, 
marked jaundice and exchange transfusion was reduced six fold in comparison to the control 
group. On the other hand the frequency of jaundice was not significantly reduced among 
the 212 infants of the mothers who received less than lg phenobarbitone in total over the 
10 day study period (Valaes et al.1980). 
For most western countries, the advent of phototherapy removed the emphasis for the prevention 
of neonatal jaundice and thus interest in antenatal phenobarbitone has waned. Whether antenatal 
phenobarbitone should be recommended for general use; restricted to predictable high risk 
groups or rejected depends on: 
1. The immediate and long term safety of the treatment.
2. The availability, costs, and relative merits of alternative methods of preventing
or treating neonatal hyperbilirubinaemia.
For the Third World countries the low cost and simplicity of antenatal phenobarbitone for 
the prevention of neonatal jaundice make it extremely attractive in comparison to the alternative 
of developing facilities for adequate monitoring of bilirubin levels and providing the necessary 
phototherapy units. 
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Evidence supports the hypothesis that antenatal phenobarbitone is effective in decreasing 
the severity of periventricular - intraventricular haemorrhage (PIVH) in low birthweight 
neonates (Barnes and Thompson, 1993). However, the decision whether antenatal pheno­
barbitone has a role in the management of neonatal jaundice depends on reaching a firm 
conclusion regarding its safety. In this regard, the authors caution that further data are necessary 
regarding the incidence of low Apgar scores and respiratory depression in low birthweight 
neonates given antenatal phenobarbitone. 
2.3.1.2 Postnatal Phenobarbitone 
The postnatal use of phenobarbitone offers the advantage of focusing the treatment to easily 
identifiable high risk groups and particularly the pre-term infants who are not covered by 
the schedules for antenatal prophylaxis. One disadvantage, however, is a time lag between 
the administration of phenobarbitone and the expression of its effect on bilirubin elimination. 
In contrast, phototherapy accelerates bilirubin elimination immediately, and for this reason 
has practical advantages over the induction of bilirubin clearance by phenobarbitone or other 
agents. The extent of individual variation in bilirubin values coupled with the paucity of 
pharmacokinetic data in newborns make it impossible to correlate bilirubin and phenobarbitone 
levels meaningfully. 
Thus no recommendation can be made regarding the dose and schedule of administration 
that will maximise the effect on bilirubin clearance from previous studies. 
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The assumption that the dose should be the same as that used for sedation or control of seizures 
is unlikely to be correct. 
From the available data it appears that the method of administration, orally or intramuscularly, 
does not influence the effect. The dosages of 5-lOmg/kg/day are probably equally effective 
and a short treatment of lOmg/kg/day for two days may be equally effective as the more 
prolonged treatment with lower dosage (Table I). 
Thus it appears that both plasma phenobarbitone levels and the length of exposure to high 
levels are important in determining the effect on bilirubin clearance. The effect of a single 
dose of 12mg/kg phenobarbitone given intramuscularly is still unknown. However, doses 
of 15-20mg/kg was required to achieve a plasma concentration in the range of 9-25mg/l 
(Painter, et al. 1989). 
The choice of 12mg/kg dose of phenobarbitone in the present study is within the range used 
clinically without producing adverse effects (Painter, et al. 1989). 
Another question not adequately answered is the earliest gestational age at which a good 
response to inducing agents can be obtained. It has been shown that the uridine-diphoshpo-
glucuronyl transferase (UDP-GT) activity increases after birth irrespective of gestational 
age, indicating that the ability to respond to the endogenous agents is not related to maturity. 
This conclusion is blurred by the simultaneous use of phototherapy, which has gained general 
acceptance as its efficacy is firmly established. 
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2. 3 .1. 3 Combination Therapy
The combination of antenatal and postnatal phenobarbitone was found to be the most effective 
schedule in infants without haemolytic disease and greater than 2 .5kg at birth (I'rolle, 1968). 
From the practical viewpoint, such a schedule is suitable for the management of pre-term 
labour and threatened delivery in combination with tocolysis and steroids. This schedule 
was found to reduce the frequency and severity of intraventricular haemorrhage in comparison 
to any other postnatal treatment. If these results are confirmed by other studies, the combined 
benefits of the treatment in reducing intraventricular haemor hage and in accelerating bilirubin 
clearance may outweigh any possible risks. 
2.3.2 RECENT THERAPEUTIC MODALITIES 
A number of agents modify bilirubin metabolism indirectly (Table IV) such as barbiturates, 
agents acting by interference with enterohepatic circulation of bilirubin, sequestrating agents, 
inhibitors of heme oxygenase and intravenous immune globulin therapy. 
I. The combination of diethylnicotinamide ( coramine) and phenobarbitone proved effective
and for some time became the standard treatment for hyperbilirubinaemia in several
centres in Europe (Enel, et al. 1969). The combination of nicotinamide with
phenobarbitone offered the advantages of the additive effect of two inducing agents,
while each of the agents was expected to neutralise the side effects of the other. The





























































































































































































































































































































































































































































































































































2. Charcoal was the first of the adsorptive agents that was tested in human neonates (Ulstrom,
et al. 1964). In normal term infants a depression of peak plasma bilirubin by30%
was observed in the infants given activated charcoal at 4 hours of life, whereas no effect
was seen in those fed charcoal at 12 hours.
3. A barbiturate derivative, bucolome was used for the prevention of hyperbilirubinaemia
in term and pre-term infants (Baba, 1972). However, in kernicteric rats, bucolome
produced an immediate decrease in plasma bilirubin levels. This was coupled with an
increase in plasma unbound bilirubin, cerebellar bilirubin content and hence subsequent
increase in mortality. Hence its use is now not currently recommended because of these
potential adverse effects.
4. Agar, a polysaccharide extracted from seaweed, has been studied extensively in neonatal
jaundice (Blum and Etienne, 1973). It binds unconjugated bilirubin with a high affinity
in aqueous solutions. However, clinical studies have not shown any benefit (Odell,
et al. 1983).
5. Cholestyramine, a cationic resin, was also studied as an adjuvant to phototherapy in
neonatal jaundice (Nicolopoulos, et al. 1984). However, it produced hyperchloraemic
acidosis and these infants required intravenous sodium bicarbonate.
6. Bilirubin oxidase, an enzyme isolated from the fungus myrothecium verrucarea and from
orange peels degrades bilirubin and is resistant to proteolytic enzymes (Mur{J,() and Tanaka.,
1981).
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Further studies are required to determine the potential clinical application of bilirubin 
oxidase in the management of hyperbilirubinaemia. 
7. The use of specific competitive inhibitors of heme oxygenase, the rate limiting enzyme
in the catabolism of heme, to decrease the rate of heme degradation to bilirubin in the
neonatal period, when bilirubin production exceeds the capacity for its disposition,
represents a new therapeutic modality in the clinical management of neonatal
hyperbilirubinaemia (Drummond and Kappas, 1981). Tin-protoporphyrin (SnPP), tin­
mesoporphyrin (SnMP), and other synthetic analogues of the natural metalloporphyrin
(ferroporphyrin - heme) are potent competitive inhibitors of heme oxygenase.
In contrast to other methods of controlling dangerously elevated serum levels of bilirubin, 
such as exchange transfusion, phototherapy and phenobarbitone, which are directed towards 
disposing of the excessive preformed bilirubin, competitive inhibition of heme oxygenase 
acts by suppressing the formation of bilirubin. SnPP and SnMP bind more avidly than 
heme to the catalytic site of heme oxygenase, but because the central metal atom, tin, 
cannot bind molecular oxygen, the enzymatic degradation of the metalloporphyrin to 
bilirubin does not occur. The inhibition of heme degradation to bilirubin does not result 
in the accumulation of heme. Instead, SnPP increased the bilirubin excretion of heme 
in amounts that fully compensated for the decreased excretion of bilirubin. 
The ability of SnPP to ameliorate the course of hyperbilirubinaemia in neonates maybe 
considered to be the net result of complex events that most likely include: 
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a. intensification and prolongation of the alternative pathway of heme excretion in
the bile with commensurate reduction in bilirubin formation
b. increased elimination of heme in faeces
c. enterohepatic circulation of heme
d. heme degradation by the developing hacterial flora.
Recently it has been reported that the prolonged use of a heme oxygenase inhibitor resulted 
in haematological and iron metabolic indices consistent with the development of reversible 
iron deficiency state (Attalah, et al. 1993). 
Thus in conclusion, the competitive inhibition of heme oxygenase by synthetic 
metalloporphyrins offers a simple solution, hut the efficacy achieved with the doses 
and compounds used thus far are not comparable with that of phenobarbitone. 
8. More recently, a multicentre controlled trial evaluated the use of high dose intravenous
human-derived immunoglobulin (HDivlg) therapy (Jochen, et al. 1992.) for the treatment
of hyperbilirubinaemia caused by rhesus haemolytic disease. It was concluded, that
immunoglobulin therapy, by a yet unknown mechanism, reduces serum bilirubin levels
and consequently, the need for blood exchange transfusions, in children with rhesus
haemolytic disease. No side effects were observed. The optimal dose of HDivlg therapy,
the most efficacious number of infusions, cost effectiveness, and the best preparation
remains to be determined. Presently, a similar study is underway at the University of
Natal, Medical School on the use of HDivlg for neonatal hyperbilirubinaemia.
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2.3.3 CONCLUSION 
In conclusion, we cannot assume that 1 or 2 days of phototherapy, the interruption of nursing 
for 48 hours or merely an expression of concern about jaundice are benign events that have 
no adverse consequences for mothers and infants in the early postnatal period. 
In fact the mere presence of neonatal jaundice (and the aura of alarm that it engenders) has 
negative consequences for maternal behaviour and attitude in the early crucial months of 
infant development. Laboratory investigations are initiated and often repeated in normal 
infants with physiological jaundice. These tests are painful for the infant, distressing to 
the parents, costly and rarely enlightening. Consequently, a simple effective regimen with 
a single dose of phenobarbitone will obviate these traumatic invasive investigations. 
If parenteral phenobarbitone is shown to effectively decrease bilirubin levels, the potential 
benefits would be a decrease in exchange transfusion rates, decrease duration of hospital 
stay, fewer days of phototherapy with its associated side-effects. If the research shows that 
there is a reduction in serum bilirubin levels and or duration of hospital stay, it would be 
quite justifiable to use phenobarbitone rather than phototherapy in this common situation 




Phenobarbitone was the first effective organic anti-epileptic agent (Hauptmann, 1909). 
It has a relatively low toxicity, is inexpensive, and is still an effective and widely used 
drug for this purpose. 
2.4.2 CHEMISTRY 
Phenobarbitone is also known as phenobarbital (Luminal®, Gardena!®). The structural 













STRUCTURE OF PHENOBARBITONE 
2.4.3 PHARMACOKINETICS 
Table V describes the pharmacokinetic parameters of phenobarbitone (Miller and 
McFadyen, 1992). 
2.4.3.1 Absorption 
Phenobarbitone is well absorbed after oral, rectal and intramuscular administration. 
Peak plasma concentration of phenobarbitone usually occurs 6-18 hours after oral 
dosing though shorter times to peak plasma level have been reported (Lous, 1954 and 
Wilensky, et al. 1982). After intramuscular administration peak plasma concentration 























Time course of plasma phenobarbitone levels a her 180mg of the drug o;..,en by lho in­
tramuscular and 0<al routes. 144 hours apart. 
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Serum half-life, may be up to about 75 hours in children. After an intramuscular dose 
of 10mg per kg, plasma concentration of 9, 12 and 13ug/ml are obtained at 30, 90 and 
120 minutes respectively (Gal, 1986). Extensive literature searches were unsuccessful 
in providing pharmacokinetic data on South African Black neonates. 
.•.· • c'x"'���lt''r>•: 




Conversion factor 4.3 
Bioavailability (F) 1 
Salt factor 0.91 
Volume of distribution (L/kg) 
Children 0.70 ± 1.0 








Neonates 103 - 115 
Time to steady state (days) 10 -16 
(3-4 weeks) 




Elimination in urine(%) 20-40
Modified from: A Practitioners guide to 
Optimum use of Anti-Epileptic drugs, 1992 (Miller & McFadyen) 
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2.4.3.2 Distribution 
Phenobarbitone distributes readily into most body tissues and approximately 50% is 
bound to plasma proteins. The distribution is sensitive to variations in the pH of 
plasma with acidosis and alkalosis causing increased tissue and serum concentrations 
respectively (Gal, 1986). The concentration of phenobarbitone in the cerebrospinal 
(CSF) averages between 43 and 52 % of that in the plasma, and salivary concentrations 
are between 30 and 38% of the plasma concentrations (Eadie, 1968). The apparent 
volume of distribution (Vd) of phenobarbitone is 0. 7 to 1.0 I/kg (Hvidberg and Dam, 
1976) with studies in neonates providing a mean value of 0.97 ± 0.20 I/kg (Pitlick, et 
al. 1978). 
2.4.3.3 Metabolism 
The metabolism of phenobarbitone has been reviewed by Whyte, et al. ( 1977). Most of 
the drug is probably eliminated by metabolism as little appears in the urine unchanged. 
The main oxidised metabolite is a phenolic derivative. About 30% of a dose may 
appear as the 1-N-glucoside metabolite. 
2.4.3.4 Elimination 
Phenobarbitone elimination follows linear pharmacokinetics. Approximately 20-40% of 
administered phenobarbitone is excreted in the urine while the remainder is metabolised 
in the liver to inactive metabolites. In general, clearance varies with age. It is fastest 
in children (8.2m1/hr/kg) and slower in adults (3.2ml/hr/kg). Clearance is highly 
variable in neonates and is on average similar to adults. This is reflected in the half-life 
which is 96 hours in adults, 103 to 115 hours in neonates and 62 hours in children 
(Pitlick, et al. 1978). Due to long half-life and smaII fluctuations in plasma 
concentrations, phenobarbitone can be administered as a single dose at night in most 
children (Davis, et al. 1981, Walson, et al. 1980). 
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2.4.4 ENZYME INDUCTION AND MODE OF ACTION 
Many enzymes are able to increase in amount and activity in response to certain 
substances known as inducers. The liver microsomal cytochrome P-450 system is 
readily induced by many drugs and other exogenous compounds. Phenobarbitone is an 
example of an efficient enzyme inducer. Other examples are phenylbutazone, phenytoin 
and polycyclic hydrocarbon insecticides, such as DDT and chlordane. 
Hydrocarbons in tobacco smoke are very strong inducers of the microsomal drug­
metabolising system (Goodman and Gilman, 1985). Several studies have shown that 
smokers have a more rapid biotransformation of drugs (shorter plasma half life) than do 
non-smokers. 
Most of the hepatic drug metabolising enzymes are induced by phenobarbitone and thus 
the metabolism of a wide range of drugs is enhanced by phenobarbitone pre-treatment. 
The common drugs involved are paracetamol, phenytoin and warfarin. Enzyme 
induction by phenobarbitone has been applied to the treatment of hyperbilirubinaemia in 
which phenobarbitone induces the activity of glucuronyl transferase which converts 
bilirubin to the glucuronide (Levi, et al. 1970). It is this enzyme inducing property 
of phenobarbitone which forms the basis of this study. 
2.4.5 ADVERSE EFFECTS 
PotentiaHy life threatening effects although rare include exfoliative dermatitis, 
agranulocytosis, aplastic anaemia and hepatitis (Schmidt, 1985). Adverse effects of 
barbiturates include respiratory depression, sedation, and occasional allergic reactions 
particularly affecting the skin (1-3%). With excessive doses, irritability and 
hyperexcitability, nystagmus, ataxia have been reported particulary in children. 
Hypoprothrombinaemia has occurred in infants of mothers who had received 
phenobarbitone in pregnancy (Mountain, et al. 1970). 
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2.4.6 SAFETY OF PERINATAL PHENOBARBITONE 
Barbiturates, being among the most frequently used drugs during pregnancy and the 
perinatal period, have been studied extensively regarding their potential for immediate 
and long term untoward effects. In humans, few immediate and no long term 
undesirable effects have been described after many years of therapeutic use of 
phenobarbitone in the perinatal period. Moreover, the use of phenobarbitone for the 
prevention of neonatal jaundice constitutes, in many ways, a different type of perinatal 
exposure that results from its use in epileptic mothers, or for neonatal seizures or for 
intra-partum sedation and anaesthesia (Goodman and Gilman, 1985). No sedation or 
withdrawal effects were observed after antenatal phenobarbitone for the prevention of 
neonatal jaundice. The absence of sedation was consistent with cord blood levels of 2-
lOmcg/ml. However, a sedative effect was observed with postnatal phenobarbitone 
particularly when high doses (20mg/kg) were used (Guys Paediatric formulary, 1990). 
Severe haemorrhagic disease of the newborn owing to depression of the vitamin K­
dependant clotting factors is a well defined complication in infants of epileptic mothers 
treated with phenobarbitone and other anti-convulsants that have hepatic enzyme 
inducing properties. This may be due to hypoprothrombinaemia induced by 
phenobarbitone, leading to a bleeding tendency in the neonate. 
The clotting abnormalities are rapidly corrected by the administration of 1 mg of vitamin 
K given at birth. This still leaves the possibility of minor obstetric trauma producing 
life-threatening haemorrhage and administration of 10mg vitamin K to the mother is 
recommended (Mountain, et al. 1970). 
2.4. 7 POPULATION PHARMACOKINETIC DATA ANALYSIS - THE 
NONMEM APPROACH 
Population pharmacokinetics describes the variability a drug exhibits in terms of a 
number of factors called fixed and random effects. 
The fixed effects are the population average values of pharmacokinetic parameters 
which may in tum be a function of various patient characteristics such as: 
a. age, weight, height and sex
b. underlying pathology such as renal or hepatic impairment
c. other influences on drug disposition such as concomitant drug therapy,
smoking and alcohol intake.
The random effects quantify the amount of pharmacokinetic variability which is not 
explained by the fixed effects i.e. inter- and intra-subject variability. Estimation of 
these fixed and random effects allows 
1. The design of dosage regimens which will, in general, suit patient groups
who are at particular risk, e.g. the elderly or those with impaired renal or
hepatic function.
2. The design of individual dosage regimens and their optimisation by means
of Bayesian feedback techniques.
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In order to determine the influence of fixed and random effects, the Nonlinear Mixed 
Effects Model (NONMEM) computer programme was developed by Beal and Sheiner in 
1980. This programme treats the population as the unit of analysis, rather than the 
individual, and in general requires fewer data points per individual (but many more 
individuals) than are normally required in a standard pharmacokinetic study. In this way 
a more representative sample of the target population can be obtained and quantitative 
relationships between pharmacokinetic parameters and pathophysiologic features can be 
investigated in a single step. These relationships may then explain a considerable 
amount of inter-subject variability present in the population (Sheiner, Rosenberg B and 
Marathe, 1977). 
Pharmacokinetic studies are often not representative of the patient population in whom 
the drug is used therapeutically. The experimental protocol, for various reasons, has to 
exclude many of the clinical cases who are later treated with the drug. Consequently, 
investigations are performed in a more homogenous group of individuals, commonly 
healthy volunteers. Evaluation of the simplest pharmacokinetic model, the one-
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compartment open model and i.v. holus injection, requires at least 5 to 6 serum 
concentration measurements in each subject if reliable estimates of the two parameters, 
clearance and volume of distribution, are to be obtained. The NONMEM approach 
permits the use of unsystematically sampled serum concentrations and few 
measurements per individual to determine the mean population parameters and their 
inter-individual variability (Sheiner, Rosenberg and Melmon, 1972). 
The statistical model used in this system is based on the reasonable premise that the 
individual pharmacokinetic parameters of a patient population arise from a distribution 
which can be described by the population mean and the inter-individual variance. 
Thus, each individual pharmacokinetic parameter can be expressed as a population mean 
and a deviation, typical for that individual. The deviation, i.e. the difference between 
the population mean and the individual parameter, is assumed to be a random variable 
and is referred to as the inter-individual variation (Vozeh, et al. 1982). 
The variability that occurs between patients (inter-individual) and within a patient (intra­
individual) causes the average pharmacokinetic data to achieve different plasma 
concentrations in each patient. A major goal of pharmacokinetic research is to identify 
those factors that may significantly alter a drug's pharmacokinetics (i.e. age, weight, 
disease states, other drugs) and to adjust appropriately the dosing scheme. A second 
goal is to quantitate the degree of inter- and intra-individual pharmacokinetic variability 
in the population. With this information one can predict the average concentration and 




3.0 AIMS OF THE STUDY 
1. To evaluate the role of parenteral phenobarbitone in neonatal hyperbilirubinaemia
m:
a. decreasing serum bilirubin more rapidly than phototherapy alone
b. decreasing duration of phototherapy and hospital stay.
2. To derive pharmacokinetic data for phenobarbitone in South African Black
neonates.
3.1 PATIENTS AND METHODS 
This was a prospective, randomised controlled study conducted at the neonatal unit of 
King Edward VIII Hospital, Durban. 
All full-term jaundiced but otherwise healthy newborns selected for phototherapy were 
eligible for inclusion in this study. 
The indications for eligibility into the study were bilirubin levels as follows 
Day 1 170-204 umols/1 
Day 2 
Day 3 




This guideline is derived from the protocol used at the King Edward VIII Hospital. For 
levels exceeding these an exchange transfusion was performed. The gestational age was 
> 37 weeks as assessed according to the scoring system of Dubowitz, et al. 1970. The
age ranged from day Oto day 7. A mass of > 2.5kg was a requirement for inclusion 
into the study. All patients were randomized to receive either phototherapy alone 
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(control group) or phototherapy plus phenobarbitone (study group). The dose of 
phenobarbitone (Sodium Gardenal® 200mg/ml) administered was 12mg/kg/body weight 
intramuscularly as a single dose. Informed and written consent were obtained from all 
parents prior to entry to the study. All neonates (both in the control and study groups) 
were placed under pbototherapy units, eyes protected by a band to prevent retinal 
damage. 
The exclusion criteria were as follows: 
1. Patients who received any prior therapy for hyperbilirubinaemia.
2. Those patients with history or evidence of infections, cephalhaematomas,
severe dehydration, birth asphyxia or any other illness.
3. Patients administered any medication known to interact with phenobarbitone
or bilirubin (enzyme inducer or inhibitor).
4. Patients born to mothers who received enzyme inducing (e.g.
phenobarbitone) or inhibiting agents (e.g. cirnetidine) in the antenatal
period.
5. Patients on any other concomitant medication.
3.2 PROCEDURES 
The time of phototherapy or phenobarbitone administration was regarded as hour 0. 
Phenobarbitone was administered with a graduated insulin syringe for accuracy. 
Venous blood samples were obtained every 4 hours for the first 24 hours and 24 hourly 
thereafter and assayed for total serum bilirubin (TSB) and phenobarbitone. Total serum 
bilirubin determinations were performed immediately by the Blood Bank of the Natal 
Blood Transfusion Services, King Edward VIII Hospital, according to the 
spectrophotometric method (Levkoff, et al. 1970). 
All patients in the study were monitored at two hour intervals for the first 24 hours and 
6 hourly thereafter by medical and nursing staff. Respiratory, neurological, 
cardiovascular and hydration status were assessed. Blood exchange transfusion was 
performed if a bilirubin level exceeded the recommended exchange level during the 
study. 
3.3 INVESTIGATIONS 
The following investigations were performed on all patients on entry into the study 
• Full blood count with smear and reticulocytes.
• Blood groups of mother and patient.
• Rhesus status of mother and patient.
• Coombs test.
• Liver function test and lactate dehydrogenase (LDH).
• GJucose-6-phosphate dehydrogenase levels (G-6-PD) ( males and females).
• Reducing substances in the urine.
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3.4 PHENOBARBITONE SERUM CONCENTRATION DETERMINATION 
The serum phenobarbitone levels was assayed using a fluorescence polarisation 
immunoassay method (Abbott TDx Clinical Analyzer), at the Drug Studies Unit, 
Department of Pharmacology, University of Durban-Westville. The lowest 
concentration that can be detected with 95% confidence by the TDx is 0.34 ug/ml. 
Venous blood samples were collected into plain glass venoject tubes, allowed to clot, 
and then centrifuged. The serum was separated into PVC tubes and stored at -20 
degrees celsius until ready for analysis. Frozen samples were allowed to thaw at room 
temperature prior to analysis. 
The instrument was operated according to manufacturer's instructions. After 
calibration, 3 quality control samples were analysed with every batch of 9 samples 
(representing 1 patient). Measured values which appeared to deviate from the expected 
profile were reassayed. Samples were also reassayed if the controls were not within 
10% of the labelled concentration. 
3.5 NONMEM ANALYSIS - METHOD 
The population pbarmacokinetic analysis was performed on a 80486 IBM-compatible 
personal computer using Double precision NONMEM - Version III - Level 1.2 and the 
PREDPP package at the Department of Pharmacology, University of Durban-Westville 
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(Boeckmann, Sheiner and Beal, 1991). Whereas NONMEM is a general nonlinear 
regression analysis tool, PREDPP is specialised to the kind of predictions which arise in 
phannacokfoetic data analysis. Data was captured into Quattro Pro Version 4.0, written 
to a standard text file and then processed by the NM-TRAN programme, a control 
language translator and pre-processor to the NONMEM programme. The NM-TRAN 
programme re-organises the data into a format suitable for use in the NONMEM 
programme. 
The sub-routine ADV AN 1 and TRANS 2 were chosen from the PREDPP library of 
sub-routines. ADVAN 1 implements the one-compartment (monoexponential) model, 
without first order absorption while TRANS 2 translates the elimination rate constant 
Ke into the pharmacokinetic parameters of clearance (Cl) and volume of distribution 
(V d). In this study, the first blood sample was drawn many hours after drug 
administration, hence the assumption that absorption was complete, and, for purposes of 
data analysis, immediate. (An examination of Figure 7 confirms this assumption as 
valid). 
3.6 STATISTICAL ANALYSIS 
The results were subjected to appropriate statistical analyses including Repeated 
Measures Analysis of Variance (ANOVA), Chi-Square, and student t-test using the 
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Forty four jaundiced Black neonates ( 2 7 males, 1 7 females) were included in the study 
(Table VI). All patients were otherwise, healthy newborn infants with a birth weight of 
� 2.5kg. The gestational age of all patients was > 37 weeks. The study group 
comprised 22 newborns who received phenobarbitone in addition to phototherapy while 
the control group numbered 22 and received phototherapy only. ABO incompatibility 
(Table VII) was observed in both study and control groups (13 and 7 respectively). 
There were 6 Coombs positive patients in the study group and 4 in the control group. 
Five patients in the study group and 2 in the control group presented with both ABO 
and Coombs positivity. As seen from Table VIII most of the patients were in the post­
natal age range Day 2 to Day 5. 
4. 1 PHENOBARBITONE ANALYSIS
A total of 198 serum samples from 22 subjects were analysed for serum phenoharbitone 
concentration (Appendix B). Phenobarbitone serum concentrations were below the level 
of detection by the instrument in 3 patients and unusually high in 1 patient. These 
patients were excluded from further data analysis. 
Figure 7 represents individual graphs of serum phenoharbitone concentration versus 
time (n = l 8). Serum levels ranged between 5 to 25 ug/ml in the 120hr sampling 
period. With the exception of one, all other serum concentrations showed a steady 
decline with time. 
Figure 8 is a NONMEM fit of the data (phenobarbitone concentration versus time) for 
all subjects represented in Figure 7. The curve labelled "typical patient" is the profile· 
exhibited by the "average" patient in the population under study. The points depict the 
measured serum concentrations at each time point for each patient in the study. 
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During the initial analysis using NONMEM, available demographic factors were plotted 
against the NONMEM predicted serum phenobarbitone concentrations in order to 
investigate the importance of these factors in explaining inter-individual variability. A 
strong relationship with mass, but no other demographic factor, was suggested. The 
influence of mass is important as it helps to determine whether neonatal phenobarbitone 
doses should be individualised according to body mass or whether a fixed dose could be 
used. 
In an attempt to determine the influence of patient mass on phenobarbitone 
pharmacokinetics, various models were tested (Table IX). In deciding whether a 
particular model was useful or not, the primary criterion evaluated was the change in 
the minimum value of the objective function (MOBF). A change in the MOBF of 3.8 
is statistica11y significant at the p < 0.05 level while a change of 7 .8 is significant at p 
< 0.005 assuming a Chi-square distribution. 
4.2 NONMEM HYPOTHESIS TESTING (TABLE IX) 
1. Model 2 vs Model 1
The hypothesis that was tested was whether mass influenced Cl (and not Vd) in a linear 
relationship with a calculated intercept with the y-axis. Model 2 was rejected because 
the MOBF change was not significant (305.195 - 305.652 = -0.457). 
2. Model 3 vs Model 1
The hypothesis that was tested was whether mass influenced Vd (and not CJ) in a linear 
relationship with a calculated intercept with the y-axis. Model 3 was accepted at the 
p < 0. 005 level because a change in MOBF of more than 7. 8 was noted (297 .100 -
305.652 = -8.552). 
3. Model 4 vs Model 3
The hypothesis that was tested was whether mass influenced both V d and CJ in a linear 
relationship with a calculated intercept with the y-axis. Model 4 was rejected because 


























































































































































































































































































































































































































































































































































































































































































































































































































































































4. Model 5 vs Model 3 - Refinement of Model 3
The hypothesis that was tested was whether mass influenced Vd (and not CJ) in a linear 
relationship as conducted for Mode] 3. However in Model 5, the intercept was forced 
through zero. Model 5 was rejected because the MOBF did not change. 
NONMEM analysis of neonatal serum concentration data in this study in neonates 
taking phenobarbitone resulted in clearance of 0.008 1/hr and a volume of distribution 
of 0. 84 I/kg. The inter-individual variability in Cl and V d was 52 % and 25 % 
respectively. Residual or intra-individual variability was 8. 8 % (Table IX). 
5.4.2 SERUM BILI RUBIN ANALYSIS 
The total serum bilirubin levels for 44 patients at each time point is presented in 
Appendix C. The mean serum bilirubin levels at various times are shown in Table X. 
Figure 9 graphically represents the change in mean serum bilirubin concentrations with 
time during the study period. This graph comparing the study and the control groups 
showed a steady decline from baseline which became apparent from 8 hours in the 
study group and from 12 hours in the control group. At 72 hours the bilirubin level in 
the study group was below 200umol/l while in the control group it was above 220 
umol/1. At 120 hours there was a coincidence of the two bilirubin levels. 
Figure 10 is a linear fit of mean total serum bilirubin concentration for study versus 
control group against time. This graph depicts the linear fit of the rate of fall of 
bilirubin i.e. the elimination rate of bilirubin in both groups. At all time points after 4 
hours, the rate of decline of bilirubin for the study group was greater than the control 
group. At 120 hours the levels for the study and control groups were approximately 190 
and 210umol/l respectively. There was no significant differences between the two 































































































































































































































































































































































































































































The area under the curve using the trapezoidal rule was determjned for both groups 
(Appendix E). Both area under the curve (AUC) and the normalised area under the 
curve (NAUC) were calculated and subjected to independent samples t-test. There were 
no significant differences between the study and the control groups in the means of both 
AUC and NAUC. Repeated measure analysis of variance (ANOVA) was used to 
compare the serum bilirubin levels in the two groups (Appendix F) at each time point, 
to look at the effect over time and to determine if there was a significant group and 
time interaction (i.e. to determine if groups behaved differently over time). For this 
analysis (ANOVA), data up to 20 hours were analyzed since some observations were 
missing after 20 hours due to discharge from hospital. There were no significant 
differences between the study group and the control group in terms of bilirubin levels. 
There was no significant change over time. All the times differed significantly from 
baseline but the groups did not behave differently over time. 
The number of patients with levels below 200umols/l of bilirubin at 48 and 96 hours 
were compared using the Chi-square test. At 48 hours,. the study group numbered 12/18 
(44.4%) while the control group was 6/22 (27%), a statistically non-significant result. 
At 96 hours, 15/18 (83.33%) in the study group and 14/22 (63.6%) in the control 
group were below 200umols/l (p = ns). The Chi-squared test was also used to 
compare the two groups with regard to the average time it took to reach the 'discharge 
level' i.e. 200umols/l from hospital. The average time to reach 200umol/l in the was 
67.37 hours in the study group (SD 45.26) and 73.68 hours (SD 40.86) in the control 
group. This difference was not statistically significant. 
4.3 FURTHER ANALYSIS 
A sub group analysis of ABO incompatibility versus ABO compatibility showed a 
significant difference at baseline (p = 0.0160) but no significant difference over time. 
Further sub-group analysis of the influence of Coombs positive and Coombs negative in 
the study from Day 4 to Day 6 was analysed using Unpaired samples t-test. No 
significant differences were found. Repeated measures analyses of variance were not 
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In addition, 2 of the male neonates had glucose-6-phosphate dehydrogenase deficiency. 
One neonate tested strongly positive for reducing sugars in the urine. However, on 
retesting two weeks later, the urine was found to be negative. 
4.4 SIDE EFFECTS 
During the trial, no patient presented with any serious side effects. The main side 
effects of phenobarbitone administration were drowsiness and excessive sleep. These 




The ohject of this trial was to evaluate the efficacy of phenobarbitone in reducing serum 
bilirubin levels in neonatal jaundice and hence determining if there was any clinical 
benefit in instituting this treatment. The second objective was to derive, 
pharmacokinetic parameters for phenobarbitone in Black African jaundiced neonates. 
A good deal of recent clinical research has explored the problem of jaundice in the 
healthy full-term infant. Hyperbilirubinaemia is of concern because of the relative risk 
of bilirubin toxicity to the central nervous system especially kemicterus. A review of 
the relationship between serum bilirubin and "brain damage" in term infants without 
haemolysis, found no evidence of any effect on cognitive impairment (IQ or 
development), neurologic abnormalities or hearing loss (Newman and Maisels, 1992). 
Hence, Newman and Maisels concluded that the risk of bilirubin induced damage is low 
in term infants without haemolysis. However, the difficulty arises from the fact that as 
with all other preventive measures, many subjects have to be treated to prevent the 
condition in a few. 
Interest in using phenobarbitone to decrease neonatal hyperbilirubinaemia was generated 
following the retrospective study of Trolle (1968), who reported a diminished incidence 
of neonatal jaundice among the offspring of epileptic and pre-eclamptic women treated 
with phenobarbitone during their pregnancies. This original report led to the 
assessment of the administration of phenobarbitone post-natally. 
The administration of phenobarbitone in neonatal jaundice has been suggested to induce 
the enzyme glucuronyl transferase, which is important in the conjugation of bilirubin in 
the liver. A study by Catz and Yaffe (1968) showed that the reduction of serum 
bilirubin in animals was the result of enhanced glucuronyltransferase activity, with 
increased bilirubin conjugation and bile flow. 
Levi, et al. (1970) found that with phenobarbitone therapy, the hepatic organic anion 
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binding protein 'Y' (i.e. Y-acceptor protein) was increased. This protein is responsible, 
in part, for the hepatic uptake of bilirubin. Such enhancement of liver function i.e. 
increased glucuronyl transferase activity and Y-acceptor protein probably increases the 
rate of bilirubin excretion and forms the basis of reducing the serum bilirubin 
concentration. Several clinical investigators have confirmed the capacity of 
phenobarbitone to reduce serum bilirubin levels (Yeung and Field, 1969; Cunningham, 
et al. 1969, Wong and Wood, 1973). However, the outcomes remain controversial. 
The investigation of phenobarbitone in neonatal jaundice is primarily directed towards a 
Third World population group with a high risk of severe neonatal jaundice and scarcity 
of resources for its management, especially exchange transfusion and its recognised 
associated risks. The opportunities arising from the use of phenobarbitone includes its 
relative ease of administration, inexpensiveness and availability, without increasing 
immediate morbidity and long term sequelae. 
Phototherapy is effective in decreasing serum bilirubin concentration and appears to be 
safe as judged by neurodevelopmental outcome (Schedit, et al. 1993). However, the 
separation of mother and infant by the barrier of phototherapy, together with the fear 
and anxiety engendered in the parents and the effects on bonding and breastfeeding are 
likely to have a negative impact on the mother. Two potential hazards of phototherapy 
are dehydration secondary to loose stools and retinal damage due to the effects of high 
intensity light. 
In this phototherapy era, it is difficult to demonstrate the effectiveness of 
phenobarbitone alone in the management of neonatal jaundice. As with exchange 
transfusions, phototherapy has to be included in the protocol of studies on drug 
treatment because of its proven benefits. This results in blunting of the differences in 
bilirubin values between the control and the study groups. The additional difference 
between the study and control groups becomes the parameter by which the efficacy of 
the drug treatment may be judged. 
A study by Yeung, Chan, et al. (1971) showed that the effect of phenobarbitone 
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treatment lasts longer than the course of administration. In the infant treated with 
phenobarbitone, the bilirubin levels remained significantly lower than that of the control 
infants for a further two days after cessation of treatment. 
In the present study, a single intramuscular dose of l 2mg/kg/body weight of 
phenobarbitone was used on the basis that a single, high but safe, dose would provide 
maximal induction of the UDP-Glucuronyl transferase since there is no literature which 
refers to the dose and the onset of induction in neonates. No sedation or withdrawal 
effects were observed after antenatal phenobarbitone, giving cord blood levels of 2-
1 Oug/ml, when used for the prevention of neonatal jaundice. However, a sedative 
effect was observed with postnatal phenobarbitone particularly when high doses 
(20mg/kg) were used (Guys Paediatric formulary, 1990). Therefore the dose of 
12mg/kg used in this study was considered a safe dose. 
In the present study, all patients were monitored at 2 hourly intervals for the first 24 
hours (as recommended by the Ethics Committee of the University of Natal) and .then 6 
hourly for the rest of the study period. The safety of the dose was confirmed by the 
lack of any serious side effects during this intensive monitoring period. No patient 
presented with any complications. The only side effects observed of were drowsiness 
and excessive sleep. However, these patients were easily aroused and experienced no 
problems with breast feeding. Barbiturates have been studied extensively during 
pregnancy and the perinatal period, in view of their potential for immediate and long 
term untoward effects. Few immediate and no long term undesirable effects have been 
described after many years of therapeutic use of phenobarbitone in the perinatal period. 
The use of phenobarbitone for the prevention of neonatal jaundice constitutes, in many 
ways, a different type of perinatal exposure than results from its use in epileptic 
mothers, or for neonatal seizures or for intra-partum sedation and anaesthesia (Goodman 
and Gilman, 1985). 
In the present study, there were 27 males and 17 females. The average birthweight was 
2.97kg in the study group and 3.10kg in the control group. While all patients had very 
high bilirubin levels, these values were below the recommended exchange levels as 
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practised at King Edward VIII Hospital. Of the total of 44 patients in the study most of 
the patients ( 45 .45 % ) had ABO blood group incompatibility and 22. 72 % of these were 
Coombs positive. None of the patients in the study required exchange transfusion. The 
influence of Coombs positive and Coombs negative was not statistically significant. 
This latter analysis was deliberately excluded by Vos, (1980), since in the South African 
Black population in particular, the raised development of immune anti-A or anti-B is 
known to be influenced strongly by many kinds of exogenous determinants in the 
immediate environment (Vos and Kirk, 1958). The influence of ABO incompatibility 
over time in the present study was not statistically significant. 
The retrospective study by Vos, Adhikari and Coovadia (1981), showed that ABO blood 
group incompatibility was not significantly associated with overall jaundice. However, 
it was a very important cause of severe jaundice and accounted for nearly half of the 
infants with very high bilirubin values which necessitated exchange transfusion. 
While there is a trend towards a decrease in serum bilirubin levels after phenobarbitone 
treatment the results were not statistically significant. Therefore the use of · 
phenobarbitone in the treatment of neonatal hyperbilirubinaemia cannot be supported. 
Furthermore, the duration of hospital stay was unaffected. 
In aiming for 'a kinder, gentler approach' Newman and Maisels (1992) recommend a 
relaxation in treatment schedules as follows 
Phototherapy when the semm bilimbin concentration is 225-330umolsll in neonates who 
are sick or have haemolysis and a semm bilimbin 300-375umolsll in well neonates 
without haemolysis. They recommend exchange transfusion at a serum bilirubin 
concentration of 300-400umolsll in sick neonates or those with haemolysis and at 425-
500umols/l in well neonates without haemolysis. 
A recommendation that will surprise many paediatricians is that breastfeeding should be 
interrupted in well neonates without haemolysis when the serum bilirubin is 275-
425umols/l. These new recommendations are not universally accepted, noting the 
problems of kemicterus, and other toxic potential effects of bilirubin , as well as the 
66 
effects of moderate hyperbilirubinaemia on IQ. The recommendations in the prevention 
of jaundice by good breastfeeding strategies, support for the nursing mother as well as 
avoidance of water supplementation are suggested by one view and another makes a 
plea for early use of phototherapy, stressing it is more effective and reduces prolonged 
exposure to raised serum bilirubin concentrations (Dodd, 1993). Before the above 
recommendations by Newman and Maisels can be fully endorsed, a controlled 
evaluation of the outcome of these proposals is awaited. 
The serum phenobarbitone levels measured in this study ranged from 5 - 25ug/ml and 
are consistent with predicted values based on the average mass of the study group 
(Figure 7). The decline in serum phenobarbitone levels is expected because all samples 
were drawn in the post-absorptive phase. Complete absorption from intramuscular 
injection occurs within 2 hours as shown by Graham (1978). Patient E (Appendix B) 
displayed an increase in serum phenobarbitone concentration from 2.14 (time = 4 
hours) to 18.37 (time = 8 hours) unlike the other subjects who showed a consistent 
decline in levels. This may be due to a number of reasons such as delayed absorption, 
the absorption site acting as a drug depot, sampling error and unusual individual 
pharmacokinetic characteristics. 
The appearance of the concentration-time profile is similar to that reported by Graham, 
(1978) who showed complete absorption of phenobarbitone within 2 hours, peaking at 2 
hours and declining thereafter. 
In view of the ethical constraints in this neonatal study, blood sampling had to be 
restricted to the collection of samples that were clinically indicated. This precluded the 
conduction of a standard pharmacokinetic study which would have entailed the 
collection of numerous samples to fully characterise the absorption, distribution and 
elimination phases. 
A clearance of 0.008 I/hr and a volume of distribution of 0.84 1/kg with an intra­
individual variability of 8.8% was obtained in this study. An exhaustive survey of the 
literature failed to provide any pharmacokinetic data in jaundiced Black African 
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neonates. This study therefore appears to be the first to report pharmacokinetic data for 
this population group in South Africa. The clearance derived from this study is 0.008 
I/hr. Clearance values for young children are reported as 0.012 I/kg/hr (Guelen, et 
al. 1975) which is in the upper range of the value obtained in the present study. The 
latter may be a consequence of the plasma clearance of phenobarbitone progressively 
increasing postnatally to a maximum at 4 weeks. In adolescence this value declines to 
0.004 I/hr. 
The apparent volume of distribution of phenobarbitone in neonates is reported to be 
0.97 ± 0.20 I/kg (Pitlick, et al. 1978) and 0.93 ± 0.15 I/kg (Painter, et al. 1989). 
The value of 0.84 1/kg obtained in the present study is consistent with the literature. 
Further studies in South Africa would validate these values and create a data base for 
national population pharmacokinetic parameters in neonates. 
Population pharmacokinetic parameters are required not only to predict altered 
pharmacokinetics in patients but also to adjust doses through Bayesian forecasting. 
Bayesian forecasting uses a modified non-linear regression analysis to enable one to 
incorporate previous experience into a model using the probability distributions of the 
pharmacokinetic parameters for the model. Data collected during routine clinical care 
is potentially useful for investigations of drug disposition in patient populations. 
NONMEM has the power to analyse such data (Tanigawara and Hori, 1991). 
The results obtained by the NONMEM analysis may be regarded as an average profile 
of the Black African neonatal population attending King Edward VIII Hospital in 
Durban. These results may form the basis for various clinical applications which 
include Bayesian forecasting programmes; dose prediction from steady state blood data 
and individualised dosage regimens. In addition, the pharmacokinetic parameters (Vd 
and Cl) so derived can be used in the calculation of loading and maintenance dose of 
phenobarbitone e.g. in neonatal epilepsy and intraventricular haemorrhage prophylaxis. 
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The decline of total serum bilirubin over time may be exploited as a surrogate for 
clinical end points in assessing the efficacy of phenobarbitone in neonatal jaundice. 
However, the high degree of intra-individual and inter-individual variability in absolute 
TSB concentrations presents a challenge in the assessment of drug effects on this 
marker. Sanathanan and Peck (1991) proposed the area under the curve (AUC) and 
normalised area under the curve (NAUC) as pharmacodynamic measures for assessing 
changes over time for CD4 counts in HIV patients. This may be extrapolated to TSB 
in this study. 
NAUC = normalised area under the curve, is derived by calculating AUC directly from 
observed TSB values using the trapezoidal rule, and then adjusting the AUC value for 
the initial TSB and T, the length of the time interval over which the AUC is calculated. 
ie. AUC divided by the product of T and the baseline TSB value. 
NAUC can be interpreted as the average relative change in TSB values from baseline. 
In a neonate without a compromised bilirubin metabolism, the NAUC would be 
expected to remain constant at approximately 1. Any change in this value would imply 
altered bilirubin metabolism with time. Both control and study groups would be 
expected to display decreases in the NAUC values (below 1). In order to determine 
whether a greater decrease occurred in the study group, the independent samples t-test 
was performed (Appendix 4). 
AUC and NAUC are measures of exposure to phenobarbitone plus phototherapy in the 
study group and phototherapy alone in the control group. Therefore any difference in 
these parameters in the study group will be due to phenobarbitone therapy. This 
concept forms the basis of the pharmacodynamic modelling. 
Analysis of the AUC and the NAUC using the student independent t test found that 
there were no statistically significant differences between the two groups. 
This result confirms that phenobarbitone (12mg/kg) treatment does not significantly 
decrease total serum bilirubin levels in neonatal jaundice. 
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Recommendations 
1. It remains theoretically possible that a spread of doses of phenobarbitone, greater
than 12mg/kg, may significantly decrease total serum bilirubin in neonatal
jaundice. However, there remains the possibility that higher doses of
phenobarbitone may compete with bilirubin for binding to serum albumin, and
hence displace the bilirubin. This may be compensated for by a greater increase in
glucuronidation of bilirubin and hence its elirrtination over the displacement.
Further studies to determine the trigger dose for maximum enzyme induction are
required.
2. Blood sampling should be done at least at 10 minute intervals in the first hour;
15 minute intervals for the next hour and thereafter half hourly for the next 4
hours in order to derive absorption data.
However, this poses an ethical problem as frequent blood sampling in neonates is
frowned upon.
In order to ascertain elimination data, prolonged hospitalization of the babies will
be required as elimination is slow.
3. This study should be extended to other hospitals as this would include a more
heterogeneous population with a greater number of subjects. The influence of
environment and ethnicity may be evaluated. Pharmacokinetic data thus generated
would be more representative of the South African neonatal population.
4. A study investigating day 1 term jaundiced babies with much higher bilirubin
levels than has been included in this study protocol is recommended as they
represent a very high risk group frequently requiring blood exchange transfusion.
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Conclusions 
This prospective controlled study demonstrates that a single dose of phenobarbitone of 
12mg/kg does not significantly lower total serum bilirubin levels or the duration of 
hospital stay in jaundiced Black African neonates. Furthermore, the pharmacokinetic 
data obtained in this study on Black South African jaundiced neonates are consistent 
with that reported in the literature. This study using phenobarbitone for neonatal 
jaundice and the pharmacokinetic data generated are the f irst to be reported in South 
Africa. 
THE CHILD APPEAL 
I am the child 
You hold in your hands my destiny 
You determine, largely, whether 
I shall succeed or fail 
Give me, I pray, those things that 
make for happiness, 
train me, I beg you, that I 
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BLOOD BANK {KING EDWARD VIII HOSP) STATISTICS FOR 
NEONATAL JAUNDICE 
TOTAL (YR) AVERAGE MONTH 
APRIL 1992 TO MARCH 1993
1. NEONATAL NURSERY, WARDS, CLAIRWOOD 2799 254 
2. EXCHANGE TRANSFUSIONS 195 15 
-ABO INCOMP. (COOMBS NEGATIVE) 24 02 
-ABO INCOMP. (COOMBS POSITIVE) 54 4.5 
-ABO COMPATIBILITY 18 1.5 
1984 -1992 
3. NURSERY STATISTICS
1984 1428 119 
1985 1595 133 
1986 1223 102 
1987 1009 84 
1988 1132 94 
1989 1310 109 
1990 1510 126 
1991 1594 133 
1992 1432 119 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































SERUM BILIRUBIN LEVELS WITH TIME 
ID GR .AGE HAO HR4 HRS HR12 HR16 HR20 HR48 
HR72 HR96 HR120 
1 1 3 276 280 249 258 285 268 
247 284 234 174 
2 1 2 266 350 258 326 279 
286 282 265 131 115 
3 1 2 203 190 192 190 195 195 
218 244 259 182 
4 1 3 279 238 315 180 183 195 
201 171 99 
-
5 1 2 320 263 257 248 310 269 
320 270 220 212 
6 1 4 333 319 285 284 297 155 
148 128 -
-
7 1 1 170 231 233 265 231 249 
241 178 -
-
8 1 2 236 248 245 283 251 251 
257 195 -
-
9 1 3 253 275 219 272 253 
213 182 144 
- -
10 1 2 259 203 207 186 177 
138 140 105 
-
-
11 1 2 235 228 281 288 281 
304 291 298 294 232 
12 1 2 263 272 265 251 243 
232 254 295 245 193 
13 1 2 234 219 207 198 171 
164 195 181 
-
-




15 1 6 385 337 343 340 273 286 
250 226 182 
-
16 1 4 298 285 268 235 226 175 
107 - -
-
17 1 3 321 285 282 256 289 208 
200 139 -
-
18 1 3 289 291 220 252 261 265 
197 - -
-
19 1 4 311 300 255 265 253 260 
210 177 -
-
20 1 3 297 270 231 280 265 210 
195 - -
-
21 1 3 256 214 254 222 245 204 
190 169 -
-
22 1 6 372 310 315 298 309 306 
200 - -
-
1 2 2 298 302 311 320 293 267 
311 259 223 226 
2 2 4 316 285 335 339 283 294 
264 282 252 187 
3 2 3 211 200 205 203 214 205 
203 198 180 175 
4 2 3 262 242 270 256 296 281 
292 266 249 229 
5 2 5 307 294 282 299 300 294 
282 183 155 
-
6 2 2 197 171 228 294 204 119 
123 - -
-
7 2 2 289 252 265 265 227 217 
239 183 -
-
8 2 3 256 281 290 294 314 271 
262 250 217 182 
9 2 1 186 190 192 196 189 193 
195 190 -
-
10 2 2 207 117 105 124 132 138 
- -
- -
11 2 5 303 345 281 261 262 249 
244 235 205 
-
12 2 4 321 290 367 375 283 271 
264 275 255 211 
13 2 5 312 329 340 396 295 300 272 
250 240 200 
14 2 4 294 267 271 283 289 254 280 
264 211 209 
15 2 5 309 290 222 214 200 198 185 
179 - -
16 2 5 295 233 246 211 238 224 233 
193 - -
17 2 3 264 239 253 251 300 263 253 
240 200 
-
18 2 6 342 298 324 300 291 233 210 
198 -
-
19 2 3 261 229 211 260 253 245 233 
206 -
-









22 2 3 262 236 223 210 228 200 
227 178 -
-
INDEPENDANT SAMPLES t-TEST ON MEAN TOTAL SERUM 
BILIRUBIN CONCENTRATION -











205. 5000 202.3750 
MEAN 233.6556 241.8353 
SD 30.4145 22.6809 
INDEPENDENT SAM PLES !-TEST ON STUDY VERSUS CONTROL: p = 0.505 
TABLE OF AREA UNDER THE CURVE (AUC) AND 
NORMALISED AREA UNDER THE CURVE (NAUC) 
GROUP AUC NAUC GROUP AUC NAUC 
STUDY 19048 6.170251 CONTROL 3450 3.71770 
STUDY 31760 7.478125 CONTROL 15350 5.89313 
STUDY 14806 5.352853 CONTROL 32138 8.55033 
STUDY 18702 0.076470 CONTROL 32228 8.18196 
STUDY 19958 7.830508 CONTROL 23440 8.5355 
STUDY 10538 5.729249 CONTROL 31976 9.15076 
STUDY 10718 4.760618 CONTROL 23602 7.05211 
STUDY 34204 0.631910 CONTROL 7608 5.96954 
STUDY 18506 6.828897 CONTROL 16496 5.88581 
STUDY 3976 4.247863 CONTROL 29768 9.36718 
STUDY 12522 4.644578 CONTROL 13878 7.22043 
STUDY 26810 6.310390 CONTROL 2602 3.14251 
STUDY 10234 4.848993 CONTROL 23630 7.03300 
STUDY 16954 5.668224 CONTROL 32354 8.24299 
STUDY 13208 5.385522 CONTROL 32096 8.58333 
STUDY 14484 6.021484 CONTROL 30280 8.06292 
STUDY 13612 5.139752 CONTROL 14448 5.02589 
STUDY 17536 6.741636 CONTROL 13680 5.62372 
CONTROL 16784 6.37739 CONTROL 23646 7.69318 
CONTROL 11016 5.20000 CONTROL 17100 5.63157 

















DF = 38.0 
DF = 38.0 
PROB= 0.221 
PROB= 0.232 
INDEPENDENT SAMPLES T-TEST ON NAUC GROUPED BY GROUP 
GROUP N MEAN SD 
1.000 18 6.326 1.758 
2.000 22 6.825 1.717 
SEPARATE VARIANCES T = -0.902 DF = 36.1 PROB= 0.373 






















MEAN SERUM BILIRUBIN LEVELS WITH 
STANDARD DEVIATION (SD) 
GROUP1 
N MEAN STD DEV MINIMUM 
24 282.458 50.230 170.000 
24 269.875 42.675 190.000 
24 258.250 36.686 192.000 
24 255.791 40.392 180.000 
24 248.708 39.974 171.000 
24 231.208 47.809 138.000 
24 213.041 49.410 107.000 
18 204.388 60.118 105.000 
9 206.888 62.008 99.000 
7 184.714 36.586 115.000 
GROUP2 
22 273.136 43.489 186.000 
22 253.636 52.913 117.000 
22 259.181 59.532 105.000 
22 265.181 62.243 124.000 
22 248.818 51.088 132.000 
21 235.476 48.457 119.000 
20 238.350 44.248 123.000 
18 223.833 37.242 178.000 
11 217.000 31.527 155.000 
8 202.375 19.970 175.000 
MAXIMUM 
385.000 
350.000 
343.000 
340.000 
310.000 
306.000 
320.000 
298.000 
294.000 
232.000 
342.000 
345.000 
367.000 
396.000 
314.000 
300.000 
311.000 
282.000 
255.000 
229.000 
